![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 305, Issue 1, 323-330, April 2003
-Opioid Receptor Antagonists in
the Forced Swim Test in Rats
Behavioral Genetics Laboratory, Department of Psychiatry, Harvard
Medical School, McLean Hospital, Belmont, Massachusetts (S.D.M.,
A.M.P., M.S.T., H.C.T., W.A.C.); and Department of Medicinal Chemistry,
University of Minnesota, Minneapolis, Minnesota (Y.Z., W.C.S., R.M.J.,
P.S.P.)
We showed previously that cAMP response element-binding protein (CREB)
within the nucleus accumbens (NAc) of rats regulates immobility in the
forced swim test (FST), an assay used to study depression. Because CREB
regulates expression of dynorphin (which acts at 
-opioid receptors)
in NAc neurons, these findings raised the possibility that
-receptors mediate immobility behaviors in the FST. Here, we report
that i.c.v. administration of the -antagonist
nor-binaltorphimine dose dependently decreased immobility in the
FST, suggesting that it has antidepressant-like effects. Implicating a
specific effect at -receptors, similar antidepressant-like effects
were seen after treatment with either of two novel, structurally dissimilar -antagonists: 5'-guanidinonaltrindole, which was
effective after i.c.v. but not systemic treatment, and
5'-acetamidinoethylnaltrindole (ANTI), which was potent and effective
after systemic treatment. The behavioral effects of the -antagonists
resembled those of tricyclic antidepressants (desipramine) and
selective serotonin reuptake inhibitors (fluoxetine and citalopram).
Conversely, systemic administration of the -agonist
[5
,7,8
]-N-methyl-N-[7-[1-pyrrolidinyl]-1-oxaspiro[4.5]dec8-yl]-benzenacetamide (U-69593) dose dependently increased immobility in the FST, consistent with prodepressant-like effects. The effects of the -ligands in the
FST were not correlated with nonspecific effects on locomotor activity.
Furthermore, the most potent and effective -antagonist (ANTI) did
not affect the rewarding impact of lateral hypothalamic brain
stimulation at a dose with strong antidepressant-like effects. These
findings are consistent with the hypothesis that CREB-mediated induction of dynorphin in the NAc "triggers" immobility behavior in
the FST. Furthermore, they raise the possibility that -antagonists may have efficacy as antidepressants, but lack stimulant or
reward-related effects.
This article has been cited by other articles:
|
|
 |
|
  J. V. Aldrich, K. A. Patkar, and J. P. McLaughlin From the Cover: Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action PNAS, October 27, 2009; 106(43): 18396 - 18401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Chartoff, M. Papadopoulou, M. L. MacDonald, A. Parsegian, D. Potter, C. Konradi, and W. A. Carlezon Jr. Desipramine Reduces Stress-Activated Dynorphin Expression and CREB Phosphorylation in NAc Tissue Mol. Pharmacol., March 1, 2009; 75(3): 704 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. DiNieri, C. L. Nemeth, A. Parsegian, T. Carle, V. V. Gurevich, E. Gurevich, R. L. Neve, E. J. Nestler, and W. A. Carlezon Jr Altered Sensitivity to Rewarding and Aversive Drugs in Mice with Inducible Disruption of cAMP Response Element-Binding Protein Function within the Nucleus Accumbens J. Neurosci., February 11, 2009; 29(6): 1855 - 1859. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kreibich, B. A. S. Reyes, A. L. Curtis, L. Ecke, C. Chavkin, E. J. V. Bockstaele, and R. J. Valentino Presynaptic Inhibition of Diverse Afferents to the Locus Ceruleus by {kappa}-Opiate Receptors: A Novel Mechanism for Regulating the Central Norepinephrine System J. Neurosci., June 18, 2008; 28(25): 6516 - 6525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. Carr and S. D. Mague p38: The Link between the {kappa}-Opioid Receptor and Dysphoria J. Neurosci., March 5, 2008; 28(10): 2299 - 2300. [Full Text] [PDF]
|
|
|
|
|
|
B. B. Land, M. R. Bruchas, J. C. Lemos, M. Xu, E. J. Melief, and C. Chavkin The Dysphoric Component of Stress Is Encoded by Activation of the Dynorphin {kappa}-Opioid System J. Neurosci., January 9, 2008; 28(2): 407 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Beguin, D. N. Potter, J. A. DiNieri, T. A. Munro, M. R. Richards, T. A. Paine, L. Berry, Z. Zhao, B. L. Roth, W. Xu, et al. N-Methylacetamide Analog of Salvinorin A: A Highly Potent and Selective {kappa}-Opioid Receptor Agonist with Oral Efficacy J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 188 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Knoll, E. G. Meloni, J. B. Thomas, F. I. Carroll, and W. A. Carlezon Jr. Anxiolytic-Like Effects of {kappa}-Opioid Receptor Antagonists in Models of Unlearned and Learned Fear in Rats J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 838 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Bruchas, B. B. Land, M. Aita, M. Xu, S. K. Barot, S. Li, and C. Chavkin Stress-Induced p38 Mitogen-Activated Protein Kinase Activation Mediates {kappa}-Opioid-Dependent Dysphoria J. Neurosci., October 24, 2007; 27(43): 11614 - 11623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Bruchas, T. Yang, S. Schreiber, M. DeFino, S. C. Kwan, S. Li, and C. Chavkin Long-Acting {kappa} Opioid Antagonists Disrupt Receptor Signaling And Produce Noncompetitive Effects By Activating C-Jun N-Terminal Kinase J. Biol. Chem., October 12, 2007; 282(41): 29803 - 29811. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Will, W. M. Vanderheyden, and A. E. Kelley Striatal opioid peptide gene expression differentially tracks short-term satiety but does not vary with negative energy balance in a manner opposite to hypothalamic NPY Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R217 - R226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Vortherms and B. L. Roth Salvinorin a: from natural product to human therapeutics. Mol. Interv., October 1, 2006; 6(5): 257 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Carlezon Jr., C. Beguin, J. A. DiNieri, M. H. Baumann, M. R. Richards, M. S. Todtenkopf, R. B. Rothman, Z. Ma, D. Y.-W. Lee, and B. M. Cohen Depressive-Like Effects of the {kappa}-Opioid Receptor Agonist Salvinorin A on Behavior and Neurochemistry in Rats J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Dow, D. S. Russell, and R. S. Duman Regulation of Activin mRNA and Smad2 Phosphorylation by Antidepressant Treatment in the Rat Brain: Effects in Behavioral Models J. Neurosci., May 18, 2005; 25(20): 4908 - 4916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Lu, A. M. Barr, J. W. Kinney, P. Sanna, B. Conti, M. M. Behrens, and T. Bartfai A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus PNAS, January 18, 2005; 102(3): 874 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chavkin, S. Sud, W. Jin, J. Stewart, J. K. Zjawiony, D. J. Siebert, B. A. Toth, S. J. Hufeisen, and B. L. Roth Salvinorin A, an Active Component of the Hallucinogenic Sage Salvia divinorum Is a Highly Efficacious {kappa}-Opioid Receptor Agonist: Structural and Functional Considerations J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1197 - 1203. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
